CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigate Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
13,421 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0600

RAD140

Filed under Oral Tablets. The bureau holds 63 laboratory returns for this compound from 19 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

19 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
HomopeptideCASE #VI-2026-0760A610.09.910.021 May 202621 May 2026
Hunan GoodPeptides Biotech CoCASE #VI-2026-0370X110.010.010.09 Jun 20259 Jun 2025
Tianjin Finder Chemical TFCCASE #VI-2026-0693A69.99.910.014 Nov 202516 Apr 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486A39.58.610.024 May 202624 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538A68.67.310.021 May 202621 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284A88.57.89.724 May 202624 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704A88.27.19.225 May 202625 May 2026
CellupepCASE #VI-2026-0888X18.28.28.224 Apr 202524 Apr 2025
EHZ PeptidesCASE #VI-2026-0296C28.17.88.36 May 202523 May 2026
Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347X18.18.18.17 May 20257 May 2025
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594A47.77.19.023 May 202623 May 2026
Oasis PeptidesCASE #VI-2026-0404X17.67.67.68 Jul 20258 Jul 2025
Pure Tested PeptidesCASE #VI-2026-0225X17.57.57.514 Jan 202514 Jan 2025
Precision Peptide CoCASE #VI-2026-0559X27.26.77.63 Jun 202524 May 2026
Pura PeptidesCASE #VI-2026-0307X17.17.17.121 May 202521 May 2025
HXNetCASE #VI-2026-0061X86.84.99.417 Dec 202419 Jan 2026
Zenith Jove Peptide ZJCASE #VI-2026-0570X26.15.96.214 Jan 202524 May 2026
Heman Peptide HMCASE #VI-2026-0089X14.64.64.66 May 20256 May 2025
Suaway Lab ResearchCASE #VI-2026-0488X32.82.13.316 Mar 202525 May 2026

Open any subject to view the batch-level evidence for RAD140 alone.